Clinical trial
Phase IIa Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Palmoplantar Epidermal Differentiation Disorders - Pachyonychia Congenita (pEDD-PC): KRT6A-pEDD-PC, KRT6B-pEDD-PC, KRT6C-pEDD-PC, KRT16-pEDD-PC and KRT17-pEDD-PC
NCT07893483 is registered in ClinicalTrials.gov with Orvida Pharma (formerly Kamari Pharma) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IIa Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Palmoplantar Epidermal Differentiation Disorders - Pachyonychia Congenita (pEDD-PC): KRT6A-pEDD-PC, KRT6B-pEDD-PC, KRT6C-pEDD-PC, KRT16-pEDD-PC and KRT17-pEDD-PC
- Lead sponsor
- Orvida Pharma (formerly Kamari Pharma)
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- November 30, 2027
- Enrollment
- 10 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 1 arm.
-
Treatment arm
Primary endpoints
Registered primary outcome measures; 6 primary.
-
To assess the safety of repeated doses of oral KM-023 in individuals with PC.
The incidence, seriousness, relationship, and outcome of TEAEs.
-
To assess the safety of repeated doses of oral KM-023 in individuals with PC.
Change from baseline in clinical laboratory parameters.
-
To assess the safety of repeated doses of oral KM-023 in individuals with PC.
Change from baseline in vital signs.
-
To assess the safety of repeated doses of oral KM-023 in individuals with PC.
Change from baseline in 12-lead ECG
-
To assess the safety of repeated doses of oral KM-023 in individuals with PC.
Change from baseline in physical examination.
+1 more primary endpoint
Lead sponsor's other trials
Orvida Pharma (formerly Kamari Pharma), most recent start first.